Drug binding for the treatment and / or chemosensitization of drug-resistant tumors.

摘要

The present invention relates to a drug combination including kinasa 2 (called p15) phosphoric acid inhibitor and cell inhibitor for cancer chemotherapy, which are managed simultaneously, separately or in sequence. The most popular cell growth inhibitors are platinum, Taxas, vinca alkaloids, 5-fluoroouracilo, doxorobicina, cyclophosphamide, etotide, mitomicina C, imatinb, Iressa and Velcade (vortezomib). The synergistic effect between p15 peptide and anticancer chemicals,It reduces the effective concentration of each cell in the combination by one or two orders of magnitude compared to the effective concentration of only cells. Therefore, the combined toxicity described in the invention is far lower than the reported anticancer cytotoxicity, which is a key advantage for cancer treatment. In addition, the combination of continuous management through pretreatment with p15 peptide leads to drug-resistant tumor chemotherapy against the above cell inhibitors.